Uniphar half-year trading update: EPS grows 11% as facility launch slips

Uniphar PLC has reported a solid first half of 2026, with approximately 11% growth in adjusted earnings per share and organic gross profit growth of around 7%.

Trading expectations for the full year remain unchanged, while all three divisions are said to be on track to meet their respective organic growth objectives.

The complication is Uniphar's new high-tech distribution facility in Ireland. Its launch has been pushed back to February 2027, and the revised timetable will require approximately €20 million of additional capital expenditure.

That makes this an encouraging trading update with one meaningful operational issue for investors to monitor.

Uniphar's key half-year figures

Metric	First half of 2026
Adjusted EPS growth	Approximately 11%
Organic gross profit growth	Approximately 7%
Net Bank Debt/EBITDA	2.4x
Additional facility capital expenditure	Approximately €20 million
Revised facility launch	February 2027
Interim results date	8 September 2026

Adjusted earnings per share, or adjusted EPS, measures earnings attributable to each share after excluding items management considers non-underlying.

Uniphar did not disclose revenue, adjusted EBITDA, statutory profit or cash flow figures in this update. Investors will need to wait for the full interim results on 8 September 2026 for a more complete view.

The figures and statements discussed here are taken from the original company announcement.

All three divisions delivered organic growth

Organic gross profit growth excludes the contribution from acquisitions and therefore provides an indication of how the existing business is performing.

Uniphar Pharma

Uniphar Pharma delivered high single-digit organic gross profit growth during the first half. Management expects the division to accelerate and produce double-digit organic gross profit growth across the full year.

This is the strongest full-year growth objective among Uniphar's three divisions. The business provides pharmaceutical and biotechnology companies with specialist services designed to improve access to medicines across global markets.

The implied acceleration during the second half is worth watching. The update says the division is on track, but it does not disclose the precise growth rate or explain which services and regions are contributing most strongly.

Uniphar Medtech

The Medtech division also achieved high single-digit organic gross profit growth during the half year. It remains on course to deliver growth at a similar high single-digit level for 2026 as a whole.

Unlike Pharma, this guidance does not appear to require a material acceleration during the second half. That provides some reassurance over the consistency of current trading, although supporting revenue and margin figures were not disclosed.

Supply Chain & Retail

Uniphar Supply Chain & Retail reported mid-single-digit organic gross profit growth. Management expects the division to maintain that rate for the full year.

This is the slowest-growing of the three divisions, but it still made a positive contribution. The operation includes Uniphar's Irish pharmaceutical wholesaling and retail pharmacy activities.

Taken together, the divisional update suggests growth is reasonably broad rather than dependent on one part of the group.

Full-year expectations remain unchanged

Management said Uniphar entered the second half with strong trading momentum and that its underlying expectations for 2026 remain unchanged.

Chief executive Ger Rabbette also reiterated confidence in the target of reaching €200 million of EBITDA by 2028. EBITDA means earnings before interest, tax, depreciation and amortisation, and is commonly used to assess underlying operating performance.

At least 80% of the growth required to reach that target is expected to be organic. That matters because it indicates the plan is not primarily dependent on acquisitions, even though mergers and acquisitions remain an important part of Uniphar's strategy.

The company said it continues to manage an active pipeline of acquisition opportunities while maintaining a disciplined approach to capital allocation. No potential targets, deal values or acquisition timings were disclosed.

Distribution facility delay brings an extra €20 million cost

The less comfortable part of the announcement concerns Uniphar's new high-tech distribution facility in Ireland.

The facility will now go live in February 2027, followed by a phased roll-out during the first half of 2027. Uniphar said the longer timetable allows for additional end-to-end testing and reduces execution risk during its seasonally important fourth-quarter trading period.

Taking extra time to test the facility could be sensible if it reduces the risk of disruption. A major distribution project going live during a peak trading period would carry obvious operational sensitivity.

However, the delay is not cost-free. Uniphar expects approximately €20 million of incremental capital expenditure, meaning additional investment in the project's physical and technological assets.

Investors should therefore separate two effects:

• The extended testing period may reduce implementation risk.
• The extra €20 million raises the project's total cash requirement.

The revised launch will also delay related depreciation and amortisation charges, creating a benefit to adjusted EPS expectations for 2026. This is primarily a timing effect from later accounting charges rather than evidence of stronger underlying trading.

Debt and liquidity deserve attention

Uniphar described its liquidity position as strong, with Net Bank Debt/EBITDA at 2.4 times at the end of June 2026.

The company said this reflected the expected unwind of previously communicated favourable working-capital movements. Working capital covers short-term operating items such as receivables, inventories and amounts owed to suppliers.

A 2.4x ratio means net bank debt was equivalent to 2.4 times EBITDA under the company's calculation. The update did not disclose the absolute level of net bank debt, available liquidity or finance costs.

Leverage is particularly relevant given the additional €20 million required for the distribution facility and Uniphar's continued appetite for acquisitions. The interim results should provide a clearer picture of cash generation and the group's capacity to fund both priorities.

What investors should watch on 8 September

Uniphar's trading performance appears positive: adjusted EPS grew by approximately 11%, organic gross profit increased across every division and full-year expectations remain intact.

The main negative is the distribution facility delay and associated increase in capital expenditure. Although management has presented the decision as a way to minimise execution risk, investors will want more detail on why the extra spending is required and whether the revised budget is now sufficiently robust.

When the interim results arrive on 8 September 2026, the most useful disclosures would include:

• Revenue, EBITDA and margin performance by division.
• Cash conversion and the absolute level of net bank debt.
• A fuller breakdown of the additional €20 million facility cost.
• Confirmation that the February 2027 launch remains achievable.
• Progress towards the €200 million EBITDA target for 2028.

For now, Uniphar's core operations appear to be developing in line with management's plans. The next set of numbers needs to show that this organic growth is translating into healthy cash generation while the group absorbs a more expensive distribution project.